In conjunction to his role as Vice President of IMI, Dr. Cottam also holds a position as a Director of Medicinal Chemistry at the Moores Cancer Center at the University of California, San Diego. He previously held an executive position at ICN Pharmaceuticals, Inc., where he directed the synthesis of novel small molecular weight nucleosides with immunomodulatory, anti-tumor, anti-viral, and/or anti-parasitic properties. With more than thirty years experience managing the discovery and development of numerous medicinal products, Dr. Cottam has served as a consultant to Specialty Laboratories, Inc., DynaVax Technologies, Inc., Salmedix, Inc., ICN Pharmaceuticals, Inc., and MP Biomedicals, Inc. He is the author of over 80 publications in peer-reviewed medical and chemistry journals.
Dr. Cottam received his B.S. degree in Chemistry from Arizona State University in Tempe, Arizona, a Ph.D. in Organic Chemistry from Brigham Young University, and postdoctoral training in Medicinal Chemistry from the Brigham Young University Cancer Research Center. He has been an active member of the American Chemical Society for over 35 years.